Table 2.
Characteristics of the study population by screening status
| |
All patients |
Screened patients |
Unscreened patients |
P value |
|---|---|---|---|---|
| |
(N = 18,688) |
(N = 3020) |
(N = 15668) |
|
| Characteristic | No. (%)a | No. (%)b | No. (%)b | |
| Age, years, mean (SD) |
55.0 (13.5) |
52.5 (15.4) |
55.5 (13.0) |
<0.0001 |
| Sex |
|
|
|
<0.0001 |
| Female |
10,608 (56.8) |
1305 (12.3) |
9303 (87.7) |
|
| Male |
8080 (43.2) |
1715 (21.2) |
6365 (78.8) |
|
| Race/ethnicity |
|
|
|
<0.0001 |
| White |
13,168 (70.5) |
2168 (16.5) |
11000 (83.5) |
|
| Hispanic |
2319 (12.5) |
402 (17.3) |
1917 (82.7) |
|
| Black |
2092 (11.2) |
247 (11.8) |
1845 (88.2) |
|
| Asian |
508 (2.7) |
76 (15.0) |
432 (85.0) |
|
| Other |
601 (3.2) |
127 (21.1) |
474 (78.9) |
|
| US residence |
18,090 (96.8) |
2896 (16.0) |
15194 (84.0) |
0.002 |
| HBV risk factorc,d |
5391 (28.8) |
1016 (18.8) |
4375 (81.2) |
<0.0001 |
| Birthplace |
1286 (6.9) |
220 (17.1) |
1066 (82.9) |
|
| Abnormal liver function |
368 (2.0) |
170 (46.2) |
198 (53.8) |
|
| Hepatitis (not specified) |
173 (0.9) |
90 (52.0) |
83 (48.0) |
|
| Hepatitis C |
213 (1.1) |
104 (48.8) |
109 (51.2) |
|
| Other liver conditions |
3821 (20.4) |
610 (16.0) |
3211 (84.0) |
|
| HIV |
70 (0.4) |
39 (55.7) |
31 (44.3) |
|
| Drug abuse |
39 (0.2) |
15 (38.5) |
24 (61.5) |
|
| Sexually transmitted disease |
106 (0.6) |
36 (34.0) |
70 (66.0) |
|
| History of HBV infectione |
78 (0.4) |
20 (25.6) |
58 (74.4) |
0.02 |
| Cancer type |
|
|
|
<0.0001 |
| Solid tumorf |
15,031 (80.4) |
581 (3.9) |
14450 (96.1) |
|
| Hematologic malignancy |
3657 (19.6) |
2439 (66.7) |
1218 (33.3) |
|
| Chemotherapy type |
|
|
|
<0.0001 |
| Rituximab |
1977 (10.6) |
1360 (68.8) |
617 (31.2) |
|
| Non-rituximab | 16,711 (89.4) | 1660 (9.9) | 15051 (90.1) |
Abbreviations: HBV hepatitis B virus, HIV human immunodeficiency virus, SD standard deviation, US United States.
aThe percentages represent column percentages (denominator equal to total number of patients in the study, 18,688). For example, 56.8% (10,608/18,688) of the patients in the study were women.
bThe percentages represent row percentages (denominator equal to total number of patients with the given characteristic). For example, 12.3% (1305/10,608) of the females were screened for HBV infection while 87.7% (9303/10,608) were not.
cPatients born in countries with moderate to high prevalence of HBV infection according to the Centers for Disease Control and Prevention3 or at least 1 of the following ICD-9 diagnosis codes any time before chemotherapy were considered to have a risk factor for HBV infection:
(i) abnormal liver function (codes 794.8);
(ii) hepatitis, not specific (codes 070, 070.4, 070.49, 070.5, 070.59, 070.6, 070.9, 571.4, 571.40, 571.41, 571.42, 571.49, 573.1, 573.2, 573.3, v02.6, v02.60, and v02.69);
(iii) other liver conditions (codes 571, 571.0, 571.2, 571.3, 571.5, 571.6, 571.8, 571.9, 572, 572.0, 572.2, 572.8, 573, 573.8, 573.9, 782.4, 789.1, and 794.8);
(iv) hepatitis C (codes 070.41, 070.44, 070.51, 070.54, 070.7, 070.70, 070.71, and v02.62);
(v) HIV (codes 042, 042.0, 042.1, 042.2, 043, 043.0, 043.1, 043.2, 043.3, 044.0, 044.9, 079.53, 795.71, 795.8, v08, and v65.44);
(vi) drug abuse (codes 305.9, 305.90, 305.91, 305.92, 305.93);
(vii) sexually transmitted disease (codes 054.1, 054.10, 054.19, 078, 078.10, 078.11, 078.19, 078.8, 078.88, 079.8, 079.88, 079.9, 079.98, 091, 091.0, 091.1, 091.2, 091.3, 091.4, 091.5, 091.6, 091.69, 091.7, 091.8, 091.89, 091.9, 092, 092.0, 092.9, 093, 093.8, 093.89, 093.9, 094, 094.3, 094.8, 094.89, 094.9, 095, 095.1, 095.3, 095.4, 095.5, 095.6, 095.7, 095.8, 095.9, 096, 097, 097.0, 097.1, 097.9, 099.41, 099.50, 099.51, 099.52, 099.53, 099.54, 099.55, 099.56, 099.59, 483.1, v02.7, v73.8).
dSum of patient numbers in the individual risk factor categories exceeds total number of patients with risk factors (n = 5391) since some patients had more than 1 HBV risk factor.
eWe considered patients to have a history of HBV infection if they had an ICD-9 code for HBV infection (0.70.22, 0.70.23, 0.70.30, 0.70.32, 0.70.33, 0.70.44, 0.70.51, 0.70.54, 0.70.70, v02.61, v02.62) either 1) before HBV screening test among patients who were screened, or 2) before the second chemotherapy administration among patients who did not have HBV screening.
fExcludes primary liver cancer.